Sumedha Dash: Why Whole Blood is Rarely the Answer Anymore?
Sumedha Dash, Transfusion Medicine specialist at Institute of Medical Sciences and Sum Hospital, shared a post on LinkedIn:
“Why Whole Blood Is Rarely the Answer Anymore?!
For decades, whole blood was the default response to anemia and blood loss. Today, transfusion medicine has moved far beyond this one size fits all approach.
Modern transfusion practice is built on component therapy. Instead of transfusing whole blood, we transfuse only what the patient actually needs.
Why component therapy makes more clinical sense:
- Packed Red Blood Cells (PRBCs) – Improve oxygen-carrying capacity in anemia
- Platelet concentrates – Prevent or control bleeding in thrombocytopenia
- Plasma – Correct coagulation factor deficiencies
- Cryoprecipitate – Target fibrinogen deficiency
Each component addresses a specific physiological problem, avoiding unnecessary volume overload and reducing transfusion-related risks.
The clinical impact:
- Better patient outcomes
- Lower risk of transfusion reactions and circulatory overload
- More rational and ethical use of a limited resource
- One donation benefits multiple patients, not just one
Good clinical practice and patient blood management (PBM)
At IMS and SUM Hospital, Bhubaneswar, Odisha, every unit collected is processed into full blood components, ensuring optimal utilization of each donation and delivering targeted, evidence-based transfusion support across all clinical specialties.
Whole blood still has select indications—such as massive hemorrhage protocols or specific trauma settings, but it is no longer the routine answer.
Despite the shift toward component therapy, whole blood still has a role in carefully selected clinical situations.
In cases of massive hemorrhage, particularly in severe trauma, battlefield injuries and uncontrolled acute blood loss, low-titer group O whole blood can provide rapid volume replacement along with red cells, plasma and platelets in a single product.
When time is critical and component therapy may delay resuscitation, whole blood can support early hemostasis and improve survival.
However, its use requires strict protocols, appropriate donor selection, and robust transfusion services and it is best viewed as a targeted tool for specific emergencies rather than routine transfusion practice.
However, these advanced component separation and transfusion facilities are still not universally available across many blood centers, particularly in resource-limited and peripheral settings.
As a result, patients may continue to receive whole blood by default rather than targeted components, not because it is ideal, but because it is the only option available.
Bridging this gap requires investment in infrastructure, trained manpower, quality systems, and policy support to ensure equitable access to safe and evidence-based transfusion care.
Transfusion medicine today is not about giving more blood, it’s about giving the right blood.”
Stay updated with Hemostasis Today.
-
Feb 25, 2026, 14:05Patient Perspectives on HMB in Women with Very Rare Bleeding Disorders – EAHAD
-
Feb 25, 2026, 13:36Zoltan Nagy: Antibody Response Can Shift from Recognizing the Adenoviral Protein to Targeting PF4 in Rare VITT Cases
-
Feb 25, 2026, 13:08Sam K. Saha: Same Clot Against Fast and Slow Systems
-
Feb 25, 2026, 13:04Haykaz Muradyan: The Use of REBOA in Obstetric Haemorrhage
-
Feb 25, 2026, 12:53Jan Hartmann: NexSys Plasma Collection System Receives FDA Clearance
-
Feb 25, 2026, 12:45Zain Khalpey: Secondary Stroke Prevention as The Most Important Opportunity to Reduce Disability
-
Feb 25, 2026, 12:40Jeff June: Stroke Care Is Clinically Mature, Stroke Biology Is Still Evolving
-
Feb 25, 2026, 12:36Wolfgang Miesbach: Repurposing Metformin – From Sugar Control to Thrombus Control
-
Feb 25, 2026, 12:30Bethany Brown: There Is A Need for A Validated Replacement for The Discontinued 2,3-DPG Assay